In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Bristol-Myers Squibb Company. Trade Record

NYSE:BMY Bristol-Myers Squibb Company stock gains 12.07% Exit Oct 16, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart BMY Aug 22, 2017, priceSeries
About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma. The company's products also comprise Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation; Baraclude to treat chronic hepatitis B virus; Daklinza and Sunvepra to treat hepatitis C virus (HCV); Reyataz and Sustiva to treat HIV; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; and Orencia to treat rheumatoid arthritis. It has collaborations with Portola Pharmaceuticals, Inc. to develop and commercialize andexanet alfa, an investigational agent; Apexigen, Inc. to evaluate Opdivo in combination with APX005M in patients with solid tumors; and license agreement with Nitto Denko Corporation to develop and commercialize siRNA molecules targeted at HSP47 in vitamin A. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Trade Information
Trade Type
LONG
ReliabilityScore™
93.42
Entry Date
Aug 22, 2017
Entry Price
53.97
Sell Date
Oct 16, 2017
Sell Price
60.48
Net Gain
12.07%
Hold Time
38 Trading Days